BlackRock, Inc. 13D and 13G filings for Marinus Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-07-08 4:32 pm Sale | 2024-06-30 | 13G | Marinus Pharmaceuticals, Inc. MRNS | BlackRock Inc. BLK | 1,869,949 3.400% | -2,729,329 (-59.34%) | Filing |
| 2024-01-25 4:59 pm Purchase | 2023-12-31 | 13G | Marinus Pharmaceuticals, Inc. MRNS | BlackRock Inc. BLK | 4,599,278 8.400% | 3,657,967 (+388.60%) | Filing |
| 2022-07-08 4:56 pm Sale | 2022-06-30 | 13G | Marinus Pharmaceuticals, Inc. MRNS | BlackRock Inc. BLK | 941,311 2.500% | -2,075,578 (-68.80%) | Filing |
| 2022-02-02 7:18 pm Purchase | 2021-12-31 | 13G | Marinus Pharmaceuticals, Inc. MRNS | BlackRock Inc. BLK | 3,016,889 8.200% | 936,798 (+45.04%) | Filing |
| 2021-02-02 2:56 pm Purchase | 2020-12-31 | 13G | Marinus Pharmaceuticals, Inc. MRNS | BlackRock Inc. BLK | 2,080,091 5.800% | 2,080,091 (New Position) | Filing |